Bimekizumab FDA Approved for Psoriatic Arthritis, Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis

Save

UCB announced today that the U.S. Food and Drug Administration (FDA) has approved bimekizumab-bkzx (Bimzelx) for the treatment of 3 chronic inflammatory disorders.

Limited Efficacy of Muscle Relaxants for Chronic Pain

Save

A systematic review of long-term muscle relaxant use for chronic pain suggests they may be effective in treating trigeminal neuralgia, cramps, and neck pain, but not fibromyalgia, low back pain, and other pain syndromes.

I Can't Treat Ugly (9.20.2024)

Save

Dr. Jack Cush reviews the news, journal articles and a new FDA approval for EGPA, this week on the Podcast.

Mycophenolate in New-Onset SLE

Save

How aggressively do you treat newly diagnosed new-onset systemic lupus erythematosus (SLE), or should you wait for organ involvement?

TREAT EARLIER - Methotrexate in Clinically Suspect Arthralgia Patients

Save

Lancet Rheumatology has published the results of the TREAT EARLIER trial, showing the prevention of rheumatoid arthritis may be enhanced by risk stratification, particularly in anti-citrullinated protein antibody (ACPA)-negative people with clinically suspect arthralgia.

Antidepressants for Pain are Weakly Effective

Save

University of Sydney research has found people over 65 are being prescribed antidepressants as pain treatment based on international guidelines that use limited evidence. The study found that in the last 40 years there have been only 15 trials globally focusing on the benefit of antidepressants for pain in older people. This study fills a much-needed gap in research by bringing together the information from these trials to look at the efficacy and harms of antidepressants for acute and chronic non-cancer pain in those over 65 years old.

FOREMOST: Apremilast in Early Oligoarticular Psoriatic Arthritis

Save

Increased Cardiovascular Events in Lupus

Save

A New York surveillance registry (Manhattan Lupus Surveillance Program) estimates higher rates of cardiovascular events (CVE) among systemic lupus erythematosus (SLE) patients, especially amongst younger males, Hispanic/Latinos and non-Hispanic Black patients.

BSR Guidelines for Systemic Sclerosis Management

Save

The British Society for Rheumatology (BSR) has updated its 2015 guidelines for the management of patients with sytemic sclerosis (SSc) based on published evidence, systematic literature review and expert opinion. 

Systemic Sclerosis Insights (9.13.2024)

Save

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.

Increasing Incidence of Morphea

Save

A large EMR derived cohort study of over 10,000 patients with morphea (localized scleroderma) sheds light on its prevalence and associated features.

ACR Speaks Against Repeated Cuts to Medicare Reimbursements

Save

The American College of Rheumatology has submitted its comments to the CMS regarding the proposed CY 2025 Medicare Physician Fee Schedule and Quality Payment Program rule and its impact on rheumatologists and rheumatology interprofessional team members’ ability to provide care to the 53 million Americans living with rheumatic disease.

Low Placental Transfer Rates with Risankizumab

Save

There are significant concerns about the safety of drug use during pregnancy and lactation, especially newer biologic agents. This is complicated by a lack of research. 

ACR Recommends QOL Self-Management Strategies

Save

American College of Rheumatology (ACR) experts identified research suggesting that patient self-management is not a

Consensus Guidelines on Pediatric Methotrexate Use

Save

Methotrexate (MTX) is commonly used in the treatment of pediatric inflammatory skin conditions, often for off-label indications. Consensus based recommendations were published to address 5 major subjects.

Moving Forward on RA Prevention Trials

Save

Now that multiple prevention clinical trials for rheumatoid arthritis (RA) have been completed, a group of investigators have reviewed the results and published their recommendations for future trial designs and drug development to assess interventions that may alter disease development.

Conservative Treatment of Acute Vertebral Fractures

Save

A network meta-analysis of pain outcomes in patients with acute osteoporotic vertebral compression fractures (VCFs) showed short-term success with calcitonin and NSAIDs in decreasing pain during activity, but long-term benefits were superior for teriparatide compared to bisphosphonates.

Linger on the Fingers (9.6.2024)

Save

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week with a focus on fingers and better prescriptive follow through.

CAR-T Like Effects with Bispecific Teclistamab

Save

A new chapter may have begun in the exciting story of "immune reset" therapy for difficult-to-treat autoimmune diseases, with a patient with severe refractory lupus obtaining drug-free remission after treatment with an antibody product normally used in multiple myeloma.

Does Rheumatoid Factor Influence Anti-TNF Responses in RA?

Save

Smolen and colleagues have published a subanalysis of the EXXELERATE study that showed while certolizumab pegol [CZP] concentrations and efficacy was unaffected by high titers of rheumatoid factor (RF), patients treated with adalimumab had a blunted response in the face of high RF titers.